| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Reimbursement for the 97610 code for UltraMIST products remains materially unchanged for 2026 with payment for treatment provided in the physician office, home visit, long-term care, and hospital settings remaining within $2-4 of 2025 rates. This is in line with the expectations the Company expressed in its preliminary revenue results release on October 6th.
"In light of some changes on other wound care reimbursement, and in response to numerous inquiries from investors and providers about UltraMIST reimbursement rates for 2026, we wanted to provide this informational update," said Sanuwave CEO Morgan Frank. "Final 2026 rates for 97610 are in line with the proposed rule and with our prior expectations. Changes for 2026 should be less than 1% with many providers seeing a slight increase in reimbursement. We look forward to discussing this further on our third quarter earnings call."
Posted In: SNWV
